ATE277628T1 - Behandlung von hematopoietischen zellen mit cxcr4 agonisten - Google Patents

Behandlung von hematopoietischen zellen mit cxcr4 agonisten

Info

Publication number
ATE277628T1
ATE277628T1 AT01925259T AT01925259T ATE277628T1 AT E277628 T1 ATE277628 T1 AT E277628T1 AT 01925259 T AT01925259 T AT 01925259T AT 01925259 T AT01925259 T AT 01925259T AT E277628 T1 ATE277628 T1 AT E277628T1
Authority
AT
Austria
Prior art keywords
cells
treatment
cxcr4
hematopoietic
patient
Prior art date
Application number
AT01925259T
Other languages
English (en)
Inventor
Hassan Salari
Ahmed Merzouk
Lakhdar Arab
Christopher R Tudan
Geeta Saxena
Connie J Eaves
Johanne Cashman
Ian Clark-Lewis
Original Assignee
Univ British Columbia
Chemokine Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002305036A external-priority patent/CA2305036A1/en
Application filed by Univ British Columbia, Chemokine Therapeutics Corp filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE277628T1 publication Critical patent/ATE277628T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01925259T 2000-04-12 2001-04-12 Behandlung von hematopoietischen zellen mit cxcr4 agonisten ATE277628T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002305036A CA2305036A1 (en) 2000-04-12 2000-04-12 Cxcr4 agonist treatment of hematopoietc cells
US23242500P 2000-09-14 2000-09-14
CA002335109A CA2335109A1 (en) 2000-04-12 2001-02-23 Cxcr4 agonist treatment of hematopoietic cells
PCT/CA2001/000540 WO2001076615A2 (en) 2000-04-12 2001-04-12 Cxcr4 agonist treatment of hematopoietic cells

Publications (1)

Publication Number Publication Date
ATE277628T1 true ATE277628T1 (de) 2004-10-15

Family

ID=27171219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925259T ATE277628T1 (de) 2000-04-12 2001-04-12 Behandlung von hematopoietischen zellen mit cxcr4 agonisten

Country Status (9)

Country Link
US (1) US20020165123A1 (de)
EP (1) EP1276493B1 (de)
JP (2) JP2003530355A (de)
AT (1) ATE277628T1 (de)
AU (2) AU5208101A (de)
BR (1) BR0110049A (de)
CA (1) CA2335109A1 (de)
DE (1) DE60106002T2 (de)
WO (1) WO2001076615A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
JP2002506830A (ja) * 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7091310B2 (en) 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
CA2522703A1 (en) * 2003-04-16 2004-11-04 Genebact Biotechnologies, Inc. Prophylactic and therapeutic benefits of new class of immune stimulating peptides
FI20040953A0 (fi) * 2004-07-08 2004-07-08 Jari Koistinaho Luuydinsolun stimulointimenetelmä ja luuydinsolu
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
ES2336245T3 (es) * 2005-04-08 2010-04-09 Lonza Ag Sintesis peptidica de helices alfa sobre resina de peg.
JP4839032B2 (ja) * 2005-07-13 2011-12-14 国立大学法人 岡山大学 ケモカイン受容体作用増強剤
CA2624138A1 (en) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
WO2007079460A2 (en) * 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Design of cxc chemokine analogs for the treatment of human diseases
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2493295A4 (de) 2009-10-28 2013-05-08 Ford Henry Health System Verfahren zur minimierung von läsionen infolge von strahlungsexposition
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2760992A (en) * 1956-08-28 Naphthalene
US2530369A (en) * 1948-01-29 1950-11-21 Phillips Petroleum Co Oxidation of aromatic compounds
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) * 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
JP2589094B2 (ja) * 1986-09-13 1997-03-12 中外製薬株式会社 抗悪性腫瘍剤
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2064558C (en) * 1989-09-25 2001-01-30 Ian B. Pragnell Method for inhibiting growth of stem cells
JP3022915B2 (ja) * 1990-07-17 2000-03-21 市郎 東 癌転移抑制剤
US6057123A (en) * 1991-12-23 2000-05-02 British Biotech Pharmaceuticals Limited Stem cell inhibiting proteins
EP0691988B1 (de) * 1993-03-31 2002-10-02 Pro-Neuron, Inc. Inhibitor der stammzellproliferation und seine verwendung
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6132987A (en) * 1994-01-13 2000-10-17 The Regents Of The University Of California Recombinant mammalian monocyte chemotactic protein-1 (MCP-1) receptors (MCP-1R, CCR-2)
ATE216425T1 (de) * 1994-08-13 2002-05-15 Roche Diagnostics Gmbh Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
US5990163A (en) * 1995-01-13 1999-11-23 The Salk Institute For Biological Studies Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
FR2751658B1 (fr) * 1996-07-26 1998-10-02 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) * 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
JP2002506830A (ja) * 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト

Also Published As

Publication number Publication date
WO2001076615A2 (en) 2001-10-18
AU5208101A (en) 2001-10-23
JP2009143942A (ja) 2009-07-02
AU2001252081B2 (en) 2004-12-23
JP2003530355A (ja) 2003-10-14
CA2335109A1 (en) 2001-10-12
AU2001252081B9 (en) 2005-05-05
BR0110049A (pt) 2003-07-01
WO2001076615A3 (en) 2002-02-28
EP1276493B1 (de) 2004-09-29
DE60106002T2 (de) 2006-02-02
US20020165123A1 (en) 2002-11-07
DE60106002D1 (de) 2004-11-04
EP1276493A2 (de) 2003-01-22

Similar Documents

Publication Publication Date Title
DE60106002D1 (de) Behandlung von hematopoietischen zellen mit cxcr4 agonisten
Frey et al. VEGF improves skeletal muscle regeneration after acute trauma and reconstruction of the limb in a rabbit model
Rabbany et al. Continuous delivery of stromal cell-derived factor-1 from alginate scaffolds accelerates wound healing
Maan et al. Cell recruitment by amnion chorion grafts promotes neovascularization
Mori et al. Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia
King et al. Role of White Blood Cells in Blood‐and Bone Marrow‐Based Autologous Therapies
Ning et al. Argon mitigates impaired wound healing process and enhances wound healing in vitro and in vivo
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
Yu et al. Stromal cell-derived factor-1-directed bone marrow mesenchymal stem cell migration in response to inflammatory and/or hypoxic stimuli
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
CA2567177A1 (en) Genetically engineered cells for therapeutic applications
Harper et al. Dermatological aspects of the use of Cyclosporin A for prophylaxis of graft‐versus‐host disease
EP2305276A3 (de) Zellen aus Lipoaspirat und ihre Verwendung zur Therapie
ATE440602T1 (de) Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
Hong et al. The combined effect of recombinant human epidermal growth factor and erythropoietin on full‐thickness wound healing in diabetic rat model
Talmor et al. Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction
Yang et al. Delivery of basic fibroblast growth factor using heparin-conjugated fibrin for therapeutic angiogenesis
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
DE69634982D1 (de) Verfahren zur steigerung von hematopoietischen zellen
Tsutsui et al. Treatment of cardiac disease by inhalation of atmospheric pressure plasma
Abraham et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation
DE60035035D1 (de) Injektion von autologem knochenmark in den herzmuskel
EA200500757A1 (ru) Новое применение декстрансульфата
Fioramonti et al. A case of hydroxyurea-induced leg ulcer after definitive treatment suspension in a patient affected by thrombocythemia: effectiveness of a new collagenase
Kwon et al. Regeneration of Chronic Rotator Cuff Tear in a Rabbit Model: Synergetic Benefits of Human Umbilical Cord Blood‐Derived Mesenchymal Stem Cells, Polydeoxyribonucleotides, and Microcurrent Therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties